WuXi AppTec Co., Ltd. (OTCMKTS:WUXAY) Short Interest Update

WuXi AppTec Co., Ltd. (OTCMKTS:WUXAYGet Free Report) was the recipient of a significant drop in short interest in February. As of February 13th, there was short interest totaling 2,315 shares, a drop of 53.6% from the January 29th total of 4,990 shares. Based on an average daily volume of 6,918 shares, the short-interest ratio is presently 0.3 days. Based on an average daily volume of 6,918 shares, the short-interest ratio is presently 0.3 days.

WuXi AppTec Stock Performance

Shares of WUXAY stock opened at $14.67 on Friday. WuXi AppTec has a 1 year low of $5.73 and a 1 year high of $16.35. The stock’s 50 day simple moving average is $14.40 and its two-hundred day simple moving average is $14.00.

Analyst Upgrades and Downgrades

Separately, The Goldman Sachs Group upgraded WuXi AppTec to a “buy” rating in a research report on Thursday, February 5th. One analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy”.

View Our Latest Research Report on WuXi AppTec

WuXi AppTec Company Profile

(Get Free Report)

WuXi AppTec is a global contract research, development and manufacturing organization serving the pharmaceutical, biotechnology and medical device industries. Headquartered in Shanghai and founded in 2000, the company provides end-to-end solutions that span drug discovery, development and manufacturing. Its offerings enable customers to accelerate the research and development process for small molecules, biologics, cell and gene therapies, as well as medical devices.

Key services include chemistry and biology discovery support, preclinical safety assessment, analytical and formulation development, clinical manufacturing, large-scale biomanufacturing, and quality testing.

Further Reading

Receive News & Ratings for WuXi AppTec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WuXi AppTec and related companies with MarketBeat.com's FREE daily email newsletter.